13 June 2022
Khairy Jamaluddin says relying on federal taxation to fund the public health care sector is not sustainable; it’s also fiscally difficult to raise MOH allocations from the federal budget.
Tag: health care financing
8 June 2022
A Mercer Marsh Benefits report found that insurers expect the costs of employer-sponsored medical benefits programmes in Malaysia to increase by 12% in 2022, the third highest increase in Asia.
8 June 2022
Khairy Jamaluddin suggests four key areas of health care reform: public-private partnerships, raising health care financing, preventive health care, and accountability in implementing reforms.
7 June 2022
Malaysia’s health system performance has deteriorated in this current century, having performed relatively well the century before.
3 June 2022
Sew Boon Lui, who has advanced breast cancer, says targeted therapy costs over RM6,000 monthly, chemotherapy over RM5,500 every 3 weeks, PET scans RM3,000 every 2 to 3 months; Socso covers a quarter of her chemo drug.
2 June 2022
Letter
The White Paper: Health Is Wealth – Dr Musa Mohd Nordin, Dr Yap Wei Aun & Asst Prof Dr Farhan Mohd Rusli
Good health leads to the people’s wellbeing, enhances their productivity, and better contributes to the wellbeing and prosperity of the nation.
5 April 2022
Dr Jemilah Mahmood says the cost of decanting patients to the private sector was “high” under the now-disbanded GKVSTF, when Covid-19 cases peaked during last year’s Delta wave.
31 March 2022
Letter
White Paper On Future-Proof Health System: Who Is Paying For Health Care Now? — Chua Hong Teck
There will be many more shocks, stresses, and challenges to the health care system, and Malaysia must be ready to face them in the near future.
15 March 2022
Malaysia
Health Reform White Paper Expected In November, Khairy Admits ‘Chronic Underinvestment’ In Health
Khairy Jamaluddin says proposals in the health care reform White Paper span 15 years and will survive government or ministerial changes.
28 January 2022
A cost-benefit analysis estimates that for every RM1 saved from drug price controls, about RM4.30 is lost to Malaysia, besides decreased health care access and poorer health outcomes for Malaysians.